Chinese Journal of Blood Purification ›› 2024, Vol. 23 ›› Issue (05): 356-359.doi: 10.3969/j.issn.1671-4091.224.05.008

Previous Articles     Next Articles

The cytokine adsorption effect of different hemodialysis filters in patients with hematological tumors and acute tumor lysis syndrome: a single-center retrospective study

HANG Xiao-pan1, SHEN Yao-yao2, YOU Bing1, CHEN Guang-ren1, CHEN Feng-ling   

  1. Department of Hemodialysis Center, and 2Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China
  • Received:2023-12-18 Revised:2024-03-11 Online:2024-05-12 Published:2024-05-12
  • Contact: 215000 苏州,苏州大学附属第一医院1血液透析中心 E-mail:chenfl02513@163.com

Abstract: Objective  To retrospectively study the cytokine adsorption effect of different hemodiafiltration filters on patients with hematologic malignancies who developed acute tumor lysis syndrome.  Methods  This article retrospectively analyzed 57 patients who developed acute tumor lysis syndrome and required continuous renal replacement therapy (CRRT) during their hospitalization in the Department of Hematology, The First Affiliated Hospital of Soochow University from September 2020 to September 2023. Patients were divided into an observation group and a control group based on the filter used for CRRT. The observation group used the AN69-OXIRIS filter, while the control group used the AN69-ST100 filter.  Results  The two filters had basically the same effect of renal replacement therapy. Cytokines of IL-6 (Z=8.937, P<0.001), IL-1b (t=2.177, P=0.031), IL-10 (t=4.065, P=0.009), IL-17A (t=4.382, P=0.013) and interferon-γ (t=6.812, P=0.002) decreased significantly in observation group, as compared with those in control group.  Conclusion   In patients developed acute tumor lysis syndrome during the treatment of hematologic malignancies, the use of the AN69-OXIRIS filter for CRRT will be more effective on cytokine adsorption and prognosis improvement.

Key words: Acute tumor lysis syndrome, Cytokine, Hemodialysis filter

CLC Number: